Impact of Skeletal Muscle Quality and Loss on the Outcome of Liver Transplantation

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorZhejiang University

About this trial

CT imaging-based skeletal muscle assessment has been found to predict the outcomes of many diseases. Previous evidence revealed that pre-transplant muscle quality and post-transplant muscle loss were associated with transplant outcomes. However, there is no prospective study supporting the aforementioned conclusions. This study aims to prospectively include liver transplant patients from multiple transplant centers, collecting their pre-transplant CT images as well as post-transplant CT images at specific time points. The objective is to further explore and clarify the correlation between skeletal muscle assessment and the prognosis of liver transplant patients. The goal is to provide guidance for peri-transplant health monitoring and disease intervention for liver transplant patients.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Adult patients undergoing deceased donor liver transplantation (DDLT) for the first time

Disqualifiers

Pediatric transplants

Presence of portal vein tumor thrombus according to imageing before transplantation

Presence of macrovascular invasion according to imageing before transplantation

Re-transplants

Trial population

Liver transplant patients from multiple transplant centers in China

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

800 Participants
are grouped into 4 trial groups
Group A: Myosteatotic Group
Group B: Non-myosteatotic Group
Group C: The Group with Severe Muscle Loss
Group D: The Group without Severe Muscle Loss

Trial outcomes

Primary outcomes

1

Postoperative mortality

Time frame
2024.1.1-2027.1.1
2

Postoperative recurrence of liver cancer

Specifically for the included patients who undergo liver transplantation for liver cancer

Time frame
2024.1.1-2027.1.1

Secondary outcomes

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Zhejiang University

Lead sponsor

First Affiliated Hospital of Zhejiang University

Collaborator

Shulan (Hangzhou) Hospital

Collaborator

The Affiliated Hospital of Qingdao University

Collaborator

West China Hospital

Collaborator

Huashan Hospital

Collaborator

This trial is not recruiting at the moment. You can still explore other options: